Trial Profile
Phase II Randomized Open-Label, Two-Arm Study of Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 09 Mar 2009 New trial record.